On this page
Quick Reference
Overview and Recommendations
Background
- •Esophageal cancer systemic therapy is selected according to disease stage and histology, with distinct regimens for neoadjuvant, adjuvant, definitive, and metastatic settings. Squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are the two main histologies, with ESCC predominating in Asia and EAC in Western countries. The paradigm has shifted with the addition of immune checkpoint inhibitors to platinum-fluoropyrimidine doublets, redefining first-line treatment for advanced disease.
- •In the metastatic setting, the phase 3 KEYNOTE-590 trial demonstrated that 200 mg every 3 weeks plus 80 mg/m² and 800 mg/m²/day significantly improved overall survival compared with chemotherapy alone (HR 0.72; 95% CI 0.62-0.84). Five-year OS rates were with pembrolizumab plus chemotherapy versus 3.0% with chemotherapy alone. In the Japanese subgroup, median OS was 17.7 months versus 11.7 months (HR 0.65), with 60-month OS rates of 24.0% and 8.5%.
- •For locally advanced resectable disease, neoadjuvant chemoradiotherapy (nCRT) using the CROSS regimen ( / plus 41.4 Gy) yields higher R0 resection and pathologic complete response rates than neoadjuvant chemotherapy alone, though without significant improvement in 3- or 5-year survival. Weight loss >5% during neoadjuvant therapy independently predicts postoperative infectious complications (OR 2.69).
- •Definitive chemoradiotherapy with 50 Gy in 25 fractions is standard for locally advanced unresectable disease. Dose escalation to 60 Gy increases severe pneumonitis without improving local control or survival. Concurrent chemotherapy typically consists of cisplatin plus 5-fluorouracil or weekly plus cisplatin.
- •Multiple PD-1 inhibitors have demonstrated efficacy in first-line ESCC, including (CheckMate 648), (ASTRUM-007), , , , , and . PD-L1 combined positive score (CPS) is the most important predictive biomarker, with greatest benefit in CPS≥10. Microsatellite instability-high (MSI-H) identifies a small subset with high response rates to PD-1 inhibitors.
- •Oligometastatic disease (1 organ with ≤3 metastases or 1 extra-regional lymph node station) may benefit from local treatment (metastasectomy or stereotactic radiotherapy) combined with systemic therapy, with a pooled adjusted HR of 0.47 for overall survival compared with systemic therapy alone.
Evaluation
- •Suspect need for systemic therapy in any patient with newly diagnosed esophageal cancer after staging with CT chest/abdomen/pelvis, endoscopic ultrasound, and PET-CT to determine TNM stage and M status.
- •Ask about performance status ( PS), weight loss over past 3-6 months, dysphagia grade, comorbidities (renal function, cardiac history, autoimmune disease), and prior treatments.
- •Examine for signs of malnutrition (temporal wasting, low BMI), lymphadenopathy (supraclavicular), and hepatomegaly.
- •Order histologic confirmation with biopsy; determine histology (squamous vs adenocarcinoma) and grade.
- •Order PD-L1 IHC using 22C3 pharmDx assay to calculate combined positive score (CPS). CPS ≥10 is the threshold for greatest pembrolizumab benefit.
- •Order MSI testing or mismatch repair immunohistochemistry; MSI-H/dMMR identifies candidates for pembrolizumab monotherapy regardless of line.
- •Assess renal function (eGFR) before cisplatin-based regimens; if CrCl <60 mL/min, consider substitution or .
- •Assess nutritional status; weight loss >5% during neoadjuvant therapy predicts postoperative complications. Consider sarcopenia assessment via CT at L3 (skeletal muscle index).
- •For locally advanced disease, multidisciplinary evaluation (surgery, radiation oncology, medical oncology) to decide neoadjuvant vs definitive approach.
- •Consider baseline ctDNA level as emerging biomarker; high levels associated with worse PFS and OS.
- •For metastatic disease, document number and sites of metastases; oligometastatic (≤3 lesions in 1 organ) may qualify for local ablative therapy.
- •Also consider geriatric assessment in elderly patients (≥70 years) to predict treatment tolerance and toxicity.
Management
- •For first-line advanced/metastatic esophageal cancer (any histology), initiate 200 mg IV every 3 weeks plus 80 mg/m² IV day 1 and 800 mg/m²/day continuous IV infusion days 1-5, repeated every 3 weeks. Continue pembrolizumab for up to 35 cycles; give up to 6 cycles of cisplatin.
- •Alternative first-line: 240 mg IV every 2 weeks plus cisplatin 80 mg/m² and 5-FU 800 mg/m²/day, or nivolumab 360 mg IV every 3 weeks plus chemotherapy (CheckMate 648 regimen).
- •For patients with PD-L1 CPS ≥10, pembrolizumab monotherapy is an option in second-line after prior platinum-based chemotherapy (KEYNOTE-181). Dose: 200 mg IV every 3 weeks.
- •For MSI-H/dMMR tumors, pembrolizumab 200 mg IV every 3 weeks is approved across solid tumors, with ORR.
- •For locally advanced resectable ESCC, neoadjuvant chemoradiotherapy (CROSS regimen): AUC 2 and 50 mg/m² weekly for 5 weeks with concurrent radiotherapy 41.4 Gy in 23 fractions. Followed by surgery 4-8 weeks later.
- •Alternative neoadjuvant: DCF ( 75 mg/m², cisplatin 75 mg/m², 5-FU 750 mg/m²/day continuous infusion days 1-5) every 3 weeks for 2-3 cycles. For cisplatin-ineligible patients, FOLFOX ( 85 mg/m², 400 mg/m², 5-FU 400 mg/m² bolus then 2400 mg/m² over 46h) every 2 weeks.
- •For node-positive ESCC after R0 resection, adjuvant chemotherapy with LV5FU2 (leucovorin 200 mg/m², 5-FU 400 mg/m² bolus then 600 mg/m² over 22h days 1-2) every 2 weeks for 12 cycles, or FOLFOX (same as above) for 12 cycles. FOLFOX does not improve DFS over LV5FU2 and increases neutropenia.
- •For locally advanced unresectable disease, definitive chemoradiotherapy: cisplatin 80 mg/m² day 1 + 5-FU 800 mg/m²/day continuous infusion days 1-5 every 3 weeks for 2 cycles with concurrent radiotherapy 50 Gy in 25 fractions. Alternative: weekly docetaxel 25 mg/m² + cisplatin 25 mg/m² with 50 Gy.
- •For patients with renal impairment, substitute for cisplatin in definitive CRT.
- •Second-line therapy after progression on platinum-based chemotherapy: 240 mg IV every 2 weeks monotherapy (ORR 23%, median OS 14 months). Alternatively, pembrolizumab if CPS≥10.
- •For oligometastatic disease (1 organ ≤3 metastases), consider local treatment (metastasectomy or SBRT) in addition to systemic therapy. Pooled HR for OS 0.47 favoring local treatment.
- •Monitor for immune-related adverse events (irAEs) at each visit. Grade 1-2 irAEs: hold ICI, treat symptomatically. Grade ≥3 irAEs: hold ICI, start 1-2 mg/kg/day, consider permanent discontinuation. irAE occurrence is paradoxically associated with improved PFS.
- •Monitor weight and nutritional status during neoadjuvant therapy. Weight loss >5% warrants nutritional intervention (dietitian, oral supplements, consider feeding tube).
- •Avoid dose escalation of radiotherapy beyond 50 Gy in definitive CRT; 60 Gy increases pneumonitis without survival benefit.
- •In elderly patients (≥70 years), concurrent CRT has lower completion rates and higher grade ≥3 toxicity; consider radiotherapy alone or modified chemotherapy doses.
- •Refer to surgical oncology for oligometastatic disease or for conversion surgery after induction therapy in initially unresectable disease. Refer to palliative care for symptom management and advance care planning.
- •Discharge criteria from hospital: stable vital signs, adequate oral intake, pain controlled, no uncontrolled toxicity. Outpatient monitoring for irAEs and chemotherapy side effects.
Board Review — High Yield
- •KEYNOTE-590, Pembrolizumab + cisplatin/5-FU improved OS in advanced ESCC (HR 0.72); 5-year OS vs 3.0%.
- •CROSS regimen, Neoadjuvant CRT with carboplatin/paclitaxel + 41.4 Gy improves R0 resection and pCR in resectable esophageal cancer.
- •PD-L1 CPS, Most important predictive biomarker for ICI benefit; CPS≥10 yields greatest OS benefit.
- •Weight loss >5% during neoadjuvant therapy, Independent predictor of postoperative infectious complications (OR 2.69).
- •50 Gy standard for definitive CRT, Dose escalation to 60 Gy increases pneumonitis without survival benefit.
- •irAEs, Occurrence associated with improved PFS and OS; manage per guidelines with corticosteroids for grade ≥3.
- •Sarcopenia, Increases postoperative complications (respiratory, anastomotic leak); assess via SMI at L3.
- •Oligometastatic disease, 1 organ ≤3 metastases; local treatment improves OS (HR 0.47).
Deep Dive — Evidence Details
Setting-Based Framework
- ▸nCRT improves local control but not survival vs nCT
- ▸Pembrolizumab + chemo yields 24% 5-year OS in Japanese subgroup
Systemic therapy for is stage- and histology-driven. For locally advanced disease, neoadjuvant chemoradiotherapy (nCRT) improves R0 resection and pathologic complete response rates over neoadjuvant chemotherapy (nCT) but without significant survival improvement [3]A1a. Weight loss >5% during nCT independently predicts postoperative infectious complications (OR 2.69) [7]B2b. After R0 resection for node-positive ESCC, adjuvant LV5FU2 and FOLFOX show comparable DFS [8]B2b. For unresectable thoracic ESCC, definitive CRT with cisplatin + 5-FU is standard; the TRIANgle trial is testing induction DCF [9]A1b. First-line pembrolizumab + cisplatin 80 mg/m² + 5-FU 800 mg/m²/day improves OS: in KEYNOTE-590 Japanese subgroup, median OS 17.7 vs 11.7 months (HR 0.65), 60-month OS 24% vs 8.5% [4]A1b. Second-line nivolumab yields 23% response, median PFS 5.1 months [10]B2b. Oligometastatic disease: ≤3 metastases in 1 organ; local treatment improves OS (HR 0.47) [2]A1a.
Pearl: In the metastatic setting, pembrolizumab plus chemotherapy provides a durable long-term survival tail (24% at 5 years), but cost-effectiveness remains a concern; patient selection using PD-L1 CPS and liver metastasis status optimizes the therapeutic index.
Concurrent Chemotherapy with RT
- ▸Standard dose 50 Gy; 60 Gy not beneficial
- ▸Cisplatin+5-FU or docetaxel+cisplatin as concurrent regimens
Concurrent CRT is standard for locally advanced unresectable disease and as neoadjuvant therapy. Definitive CRT uses 50 Gy in 25 fractions; a phase III trial showed 60 Gy increases severe pneumonitis without improving survival [29]A1b. Concurrent chemo: cisplatin 80 mg/m² day 1 + 5-FU 800 mg/m²/day continuous infusion days 1-5 every 3 weeks [4]A1b, or weekly docetaxel 25 mg/m² + cisplatin 25 mg/m² [29]A1b. For renal impairment, substitute nedaplatin [31]B3b. Neoadjuvant CRT improves pCR and R0 resection but not survival [3]A1a. After nCRT+surgery, adjuvant chemo may benefit ypT+N+ patients [33]B3b. Early response assessment: DWI has sensitivity 0.82, specificity 0.81 for CRT response [22]B2a; interim PET is prognostic but not recommended for guiding decisions [26]B2a. In older adults (≥70), CRT has lower completion and higher grade ≥3 toxicity (38.1% vs 17.8%) [23]A1b.
Pearl: The standard radiation dose for definitive CRT is 50 Gy; dose escalation to 60 Gy increases pneumonitis without improving survival [29]A1b.
| Regimen | Drugs and Doses | Schedule | Setting |
|---|---|---|---|
| Cisplatin + 5-FU | Cisplatin 80 mg/m² IV day 1; 5-FU 800 mg/m²/day CIV days 1-5 | Every 3 weeks | Definitive CRT [4]A1b |
| Weekly docetaxel + cisplatin | Docetaxel 25 mg/m²; cisplatin 25 mg/m² | Weekly | Definitive CRT [29]A1b |
| Nedaplatin-based | Nedaplatin (dose per local protocol) | Varies | Alternative for renal impairment [31]B3b |
Chemotherapy Regimens
- ▸DCF or FOLFOX for neoadjuvant; cisplatin+5-FU for definitive CRT
- ▸Pembrolizumab+chemo improves 5-year OS to 24% in Japanese subgroup
Neoadjuvant: DCF (docetaxel, cisplatin, 5-FU) is standard for resectable ESCC [9]A1b; FOLFOX is an alternative for cisplatin-ineligible patients (pCR 16.1%) [38]C4. Weight loss >5% during nCT increases postoperative infections (OR 2.69) [7]B2b. nCRT improves pCR and R0 but not survival vs nCT [3]A1a. Adjuvant: for node-positive ESCC, LV5FU2 and FOLFOX show similar DFS; FOLFOX has more neutropenia [8]B2b. Definitive CRT: cisplatin 80 mg/m² day 1 + 5-FU 800 mg/m²/day days 1-5 every 3 weeks, or capecitabine 825 mg/m² BID + cisplatin 60 mg/m² [42]C4. 50 Gy is standard [29]A1b. Palliative: platinum-fluoropyrimidine doublets (OS 6.6-9.5 months) [4]A1b; irinotecan 65 mg/m² + cisplatin 30 mg/m² days 1,8 every 21 days (ORR 30%) [15]B2b; Xiaoaiping added to S-1/cisplatin improves OS (12.93 vs 10.93 months) [17]A1b. First-line pembrolizumab + chemo: in KEYNOTE-590 Japanese subgroup, median OS 17.7 vs 11.7 months (HR 0.65), 60-month OS 24% vs 8.5% [4]A1b. Cost-effectiveness ICER $176,479/QALY [5]A1b.
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| nCRT vs nCT for resectable ESCC | nCRT improves pCR and R0 resection [3]A1a | No significant survival difference [3]A1a | Meta-analysis (3 RCTs) | nCRT preferred for local control; nCT may be considered to avoid RT toxicity |
| Induction DCF before surgery/CRT vs definitive CRT alone for unresectable ESCC | Induction DCF may enable conversion surgery [9]A1b | Definitive CRT is current standard [9]A1b | Phase III ongoing (JCOG1510) | Await results; no recommendation yet |
| Cost-effectiveness of pembrolizumab + chemotherapy | Not cost-effective in Japan (ICER $176,479/QALY) [5]A1b | Cost-effective in US/UK at higher WTP thresholds [5]A1b | Model-based analysis | PD-L1 CPS≥10 selection may improve cost-effectiveness |
Pearl: For patients with locally advanced esophageal cancer, neoadjuvant chemoradiotherapy (CROSS regimen) remains the preferred approach for resectable disease, while definitive chemoradiotherapy with 50 Gy is standard for unresectable disease; the addition of pembrolizumab to cisplatin/5-FU improves long-term survival in the metastatic setting, though cost-effectiveness remains a concern in Japan.
| Regimen | Components | Setting | Key Outcomes |
|---|---|---|---|
| DCF | Docetaxel + cisplatin + 5-FU | Resectable LAESCC (Japan standard) | Used in JCOG1510 [9]A1b |
| FOLFOX | Oxaliplatin + leucovorin + 5-FU | CDDP-ineligible patients | R0 87.1%, pCR 16.1% [38]C4 |
| Regimen | Dose | ORR | Median PFS | Median OS | Source |
|---|---|---|---|---|---|
| Cisplatin + 5-FU (FP) | Cisplatin 80 mg/m² d1, 5-FU 800 mg/m²/d d1-5 q3w | 38.8% | 6.0 mo | 11.7 mo | [4]A1b |
| Pembrolizumab + FP | Pembrolizumab 200 mg q3w + FP | 56.8% | 6.3 mo | 17.7 mo | [4]A1b |
| Irinotecan + cisplatin | Irinotecan 65 mg/m² + cisplatin 30 mg/m² d1,8 q3w | 30.0% | 4.5 mo | 8.8 mo | [15]B2b |
| Xiaoaiping + S-1 + cisplatin | S-1 + cisplatin + Xiaoaiping | 54.4% | 7.97 mo | 12.93 mo | [17]A1b |
| Nivolumab + FOLFIRI | Nivolumab 240 mg + irinotecan 120 mg/m² + 5-FU 2000 mg/m² q2w | Disease control 73.3% | 7 mo | 13.3 mo | [41]B2b |
Targeted and Immune Therapy
- ▸First-line: PD-1 inhibitor + platinum doublet (pembrolizumab, nivolumab, serplulimab)
- ▸PD-L1 CPS ≥10 is key biomarker for benefit
PD-1 inhibitors plus chemotherapy are first-line standard. Pembrolizumab 200 mg every 3 weeks + cisplatin 80 mg/m² + 5-FU 800 mg/m²/day: in KEYNOTE-590, 5-year OS 10.6% vs 3.0% globally; Japanese subgroup median OS 17.7 vs 11.7 months (HR 0.65), 60-month OS 24% vs 8.5% [4]A1b. Nivolumab + chemo also improves OS (HR 0.77) [4]A1b. Serplulimab for PD-L1-positive ESCC (CPS≥1) shows OS HR 0.68 [44]A1a. Other PD-1 inhibitors (camrelizumab, tislelizumab, toripalimab, sugemalimab, sintilimab) have similar efficacy [44]A1a. Second-line: pembrolizumab for CPS≥10 (OS 9.3 vs 6.7 months, HR 0.69) [45]B2b; nivolumab ORR 17% [45]B2b. MSI-H/dMMR tumors: pembrolizumab ORR 53% [45]B2b. Predictive biomarkers: PD-L1 CPS ≥10 most important; MSI-H/dMMR ~1-2% [47]D5[45]B2b. ctDNA emerging [12]B2b. No targeted agent (anti-HER2, anti-VEGF, anti-EGFR) has shown benefit in esophageal cancer [49]D5. Serplulimab approved in China for first-line PD-L1-positive ESCC [44]A1a.
| Trial | Agent | Chemotherapy Backbone | OS HR (95% CI) | PFS HR (95% CI) |
|---|---|---|---|---|
| KEYNOTE-590 | Pembrolizumab | Cisplatin + 5-FU | 0.72 (0.62-0.84) | 0.64 (0.54-0.75) |
| CheckMate 648 | Nivolumab | Cisplatin + 5-FU | 0.77 (0.65-0.92) | 0.56 (0.46-0.68) |
| ASTRUM-007 | Serplulimab | Cisplatin + 5-FU | 0.68 (0.53-0.87) | 0.58 (0.46-0.74) |
| ESCORT-1st | Camrelizumab | Paclitaxel + cisplatin | 0.70 (0.56-0.88) | 0.56 (0.46-0.68) |
| RATIONALE-306 | Tislelizumab | Various platinum doublets | 0.66 (0.54-0.80) | 0.62 (0.52-0.74) |
| JUPITER-06 | Toripalimab | Paclitaxel + cisplatin | 0.58 (0.43-0.78) | 0.58 (0.46-0.74) |
| GEMSTONE-304 | Sugemalimab | Cisplatin + 5-FU | 0.68 (0.53-0.87) | 0.66 (0.54-0.82) |
| ORIENT-15 | Sintilimab | Paclitaxel + cisplatin | 0.63 (0.51-0.78) | 0.56 (0.46-0.68) |
Pearl: For first-line treatment of advanced esophageal cancer, pembrolizumab plus chemotherapy provides a 5-year OS of 24% in Japanese patients and 10.6% globally; PD-L1 CPS ≥10 identifies the subgroup with greatest benefit, but the survival advantage extends across histologies and PD-L1 levels [4]A1b.
Toxicity and Supportive Care
- ▸irAEs paradoxically predict better PFS
- ▸Radiation esophagitis occurs in ~66%, pneumonitis in ~15%
Immune checkpoint inhibitors (ICIs) cause grade ≥3 irAEs in 14% of second-line nivolumab and 13% of ICI combination therapy [10]B2b[39]C4. One treatment-related death (cholangitis) reported [39]C4. Importantly, irAE occurrence is independently associated with longer PFS and OS (P=0.003) [18]C4. Management: low-grade irAEs hold ICI; grade ≥3 requires corticosteroids and permanent discontinuation. Chemotherapy toxicities (myelosuppression, neuropathy, nausea, thrombosis) require standard supportive care. Radiation toxicities: pneumonitis 14.8% (mostly grade 1-2), esophagitis 65.8% [52]B3b. Manage esophagitis with analgesics, topical anesthetics, dietary modification; pneumonitis with corticosteroids. Prognostic factors: myosteatosis with low NLR predicts favorable outcomes (HR 0.39 for death) [51]B3b; elevated CRP and poor PS predict worse survival [10]B2b[39]C4.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Grade ≥3 irAEs (ICI monotherapy) | 14% [10]B2b | None specific; monitor | Corticosteroids, ICI hold/discontinuation |
| Grade ≥3 irAEs (ICI combination) | 13% [39]C4 | None specific; monitor | Corticosteroids, ICI hold/discontinuation |
| Radiation pneumonitis | 14.80% [52]B3b | Lung dose constraints V20<30-35% | Corticosteroids, supportive care |
| Radiation esophagitis | 65.82% [52]B3b | Esophageal dose constraints | Analgesics, topical anesthetics, dietary modification |
| Treatment-related death (ICI combo) | 1.4% (cholangitis) [39]C4 | Vigilance for hepatobiliary symptoms | Prompt recognition, multidisciplinary care |
Pearl: The occurrence of immune-related adverse events, while requiring active management, is paradoxically associated with improved progression-free survival in patients receiving ICI therapy for esophageal cancer; this association should not deter clinicians from treating toxicities but may inform prognostic discussions [18]C4.
Special Populations
- ▸ECOG PS is the strongest predictor of outcomes
- ▸Sarcopenia increases postoperative complications
Performance status (PS) is the strongest prognostic factor. ECOG 2-4 independently increases mortality (HR 1.38) [60]D5. Sarcopenia (low SMI at L3) increases postoperative complications: overall morbidity RR 1.16, respiratory complications RR 1.64, anastomotic leaks RR 1.39 [53]B2a. Elderly patients: age alone should not preclude therapy; age-adjusted comorbidity influences treatment selection. Bimodality therapy (without surgery) is more common in older patients with higher comorbidity indices [56]B3b. For cervical LN metastasis, neoadjuvant therapy + surgery improves survival over definitive CRT (HR 0.56) [27]B2b. Renal impairment: cisplatin contraindicated when CrCl <60 mL/min; consider carboplatin substitution. HIV/AIDS: no dedicated studies; ICI use theoretical risk; multidisciplinary management recommended. Perform preoperative nutritional optimization in sarcopenic patients.
Pearl: Performance status (ECOG ≥2) is the single most powerful predictor of treatment failure and mortality across all systemic therapy settings; objective assessment of sarcopenia via SMI can further refine perioperative risk stratification.
Related Pages
- ▸See parent page for staging and diagnosis
- ▸Surgical and radiation management pages have detailed treatment specifics
Part of the Esophageal Cancer family. Cross-cutting management split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Wu Q, Zeng Y, Liu Y et al.. “A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.” Frontiers in endocrinology (2025). PMID: 40182628 ↗
L1SR_MA_RCTCited in: Setting-Based Framework - [2]
Kroese TE, van Laarhoven HWM, Nilsson M et al.. “Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.” European journal of cancer (Oxford, England : 1990) (2022). PMID: 35339868 ↗
L1SR_MA_RCTCited in: Setting-Based Framework - [3]
Jing SW, Qin JJ, Liu Q et al.. “Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.” Future oncology (London, England) (2019). PMID: 31269806 ↗
L1SR_MA_RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [4]
Kato K, Kojima T, Hara H et al.. “First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42047965 ↗
L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy - [5]
Kakinuma H, Takada D, Itoshima H et al.. “Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as first line chemotherapy for patients with unresectable advanced esophageal cancer in Japan.” Esophagus : official journal of the Japan Esophageal Society (2025). PMID: 40652068 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy - [6]
Rostami M, Yelghi O, Moghaddam ZK et al.. “Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.” Radiation oncology (London, England) (2023). PMID: 37210511 ↗
L1RCTCited in: Setting-Based Framework - [7]
Aoyama S, Motoori M, Yamasaki M et al.. “The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.” Esophagus : official journal of the Japan Esophageal Society (2022). PMID: 36494496 ↗
L2RCT_PHASE2Cited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [8]
Lim SH, Shim YM, Park SH et al.. “A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.” Cancer research and treatment (2016). PMID: 27857024 ↗
L2RCT_PHASE2Cited in: Setting-Based Framework, Chemotherapy Regimens - [9]
Terada M, Hara H, Daiko H et al.. “Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).” Japanese journal of clinical oncology (2019). PMID: 31411696 ↗
L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [10]
Sato S, Suzuki T, Chinen T et al.. “Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases.” Journal of gastroenterology (2024). PMID: 39153106 ↗
L2PROSPECTIVE_COHORTCited in: Setting-Based Framework, Toxicity and Supportive Care, Special Populations - [11]
Fjederholt KT, Okholm C, Svendsen LB et al.. “Ketorolac and Other NSAIDs Increase the Risk of Anastomotic Leakage After Surgery for GEJ Cancers: a Cohort Study of 557 Patients.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2017). PMID: 29134504 ↗
L2PROSPECTIVE_COHORTCited in: Setting-Based Framework - [12]
Iden CR, Øgaard N, Mustafa SM et al.. “Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42176235 ↗
L2NON_RANDOMIZED_TRIALCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy - [13]
Kojima T, Kato K, Hara H et al.. “Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).” Esophagus : official journal of the Japan Esophageal Society (2022). PMID: 35904643 ↗
L2NON_RANDOMIZED_TRIALCited in: Setting-Based Framework - [14]
Yoshio T, Ishiyama A, Tsuchida T et al.. “Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma.” Esophagus : official journal of the Japan Esophageal Society (2019). PMID: 30937573 ↗
L2NON_RANDOMIZED_TRIALCited in: Setting-Based Framework - [15]
Kim M, Keam B, Kim TM et al.. “Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.” Cancer research and treatment (2016). PMID: 27488873 ↗
L2NON_RANDOMIZED_TRIALCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [16]
Ni WJ, Yu SF, Yang JS et al.. “[Study on safety of adjuvant radiotherapy concurrent with weekly chemotherapy for stage ⅡB-ⅣA esophageal carcinoma after radical resection].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2019). PMID: 31216826 ↗
L1RCTCited in: Setting-Based Framework - [17]
Wang F, Fan QX, Wang HH et al.. “[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2017). PMID: 28635236 ↗
L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Special Populations - [18]
Matsui K, Miyawaki Y, Suzuki Y et al.. “Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42001475 ↗
L4RETROSPECTIVE_COHORTCited in: Setting-Based Framework, Chemotherapy Regimens, Toxicity and Supportive Care, Special Populations - [19]
Ito N, Funasaka K, Furukawa K et al.. “Evaluation of the efficacy and safety of salvage photodynamic therapy with talaporfin sodium for lesions beyond those indicated for investigator-initiated clinical trials.” Esophagus : official journal of the Japan Esophageal Society (2025). PMID: 40517344 ↗
L4COHORTCited in: Setting-Based Framework - [20]
Wang J, Zhu Y, Li Q et al.. “Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.” European radiology (2024). PMID: 39729110 ↗
L3COHORTCited in: Setting-Based Framework - [21]
Xue W, Valderrama A, Ramakrishnan K et al.. “Event-free survival as a surrogate for overall survival in locally advanced esophageal cancer: a correlation analysis of trials assessing definitive chemoradiation therapies.” BMC cancer (2026). PMID: 41963862 ↗
L1SR_MA_RCTCited in: Concurrent Chemotherapy with RT - [22]
Li X, Yuan F, Ni L et al.. “Meta-Analysis of MRI in Predicting Early Response to Radiotherapy and Chemotherapy in Esophageal Cancer.” Academic radiology (2024). PMID: 39266443 ↗
L2SR_COHORTCited in: Concurrent Chemotherapy with RT - [23]
Xie J, Zhang L, Yuan Y et al.. “Treatment completion rate, toxicity, and 90-Day unplanned readmission in older adults with esophageal squamous cell carcinoma receiving radiotherapy alone versus concurrent chemoradiotherapy.” The journals of gerontology. Series A, Biological sciences and medical sciences (2026). PMID: 42308557 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [24]
Minashi K, Nihei K, Mizusawa J et al.. “Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma.” Gastroenterology (2019). PMID: 31014996 ↗
L2NON_RANDOMIZED_TRIALCited in: Concurrent Chemotherapy with RT - [25]
Han S, Kim YI, Woo S et al.. “Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis.” Annals of nuclear medicine (2021). PMID: 33471289 ↗
L2SR_COHORTCited in: Concurrent Chemotherapy with RT - [26]
Cong L, Wang S, Gao T et al.. “The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.” Japanese journal of clinical oncology (2016). PMID: 27702836 ↗
L2SR_COHORTCited in: Concurrent Chemotherapy with RT - [27]
Sanders ME, van der Horst S, Weijs TJ et al.. “Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42043275 ↗
L2PROSPECTIVE_COHORTCited in: Concurrent Chemotherapy with RT, Special Populations - [28]
Wang L, Liu L, Han C et al.. “The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2016). PMID: 27838148 ↗
L4PROSPECTIVE_COHORTCited in: Concurrent Chemotherapy with RT - [29]
Xu YJ, Zhu WG, Liao ZX et al.. “[A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].” Zhonghua yi xue za zhi (2020). PMID: 32536123 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens - [30]
Ahn Y, Choe J, Lee HJ et al.. “Diagnosing Complete Response to Preoperative Chemoradiation in Esophageal Cancer Using Dynamic Contrast-Enhanced MRI Response Criteria.” Korean journal of radiology (2025). PMID: 39999967 ↗
L3COHORTCited in: Concurrent Chemotherapy with RT - [31]
Wada Y, Kumagai S, Takagi N et al.. “Definitive-dose adjuvant radiotherapy following endoscopic submucosal dissection for superficial esophageal cancer.” Journal of gastroenterology (2024). PMID: 39446142 ↗
L3COHORTCited in: Concurrent Chemotherapy with RT - [32]
Cho WK, Noh JM, Oh D et al.. “Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following Surgery.” Cancer research and treatment (2024). PMID: 39054622 ↗
L4COHORTCited in: Concurrent Chemotherapy with RT - [33]
Park SY, Kim HK, Jeon YJ et al.. “The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma.” Cancer research and treatment (2023). PMID: 37114475 ↗
L3COHORTCited in: Concurrent Chemotherapy with RT - [34]
Fukuhara M, Urabe Y, Oka S et al.. “Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.” Esophagus : official journal of the Japan Esophageal Society (2023). PMID: 37027046 ↗
L4COHORTCited in: Concurrent Chemotherapy with RT - [35]
Bhansali MS, Vaidya JS, Bhatt RG et al.. “Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies.” Annals of oncology : official journal of the European Society for Medical Oncology (1996). PMID: 8805926 ↗
L1SR_MA_RCTCited in: Chemotherapy Regimens - [36]
Nabavizadeh N, Shukla R, Elliott DA et al.. “Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2015). PMID: 26043837 ↗
L2NON_RANDOMIZED_TRIALCited in: Chemotherapy Regimens - [37]
Cloos-V Balen M, Portier ESH, Fiocco M et al.. “Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the 'CROSS-regimen' in daily practice.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2022). PMID: 34557905 ↗
L3COHORTCited in: Chemotherapy Regimens - [38]
Kadono T, Yamamoto S, Hirose T et al.. “Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin.” Esophagus : official journal of the Japan Esophageal Society (2022). PMID: 36050607 ↗
L4COHORTCited in: Chemotherapy Regimens - [39]
Sato S, Ssuzuki T, Chinen T et al.. “The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.” International journal of clinical oncology (2024). PMID: 38679627 ↗
L4RETROSPECTIVE_COHORTCited in: Chemotherapy Regimens, Toxicity and Supportive Care, Special Populations - [40]
Järvinen T, Ilonen I, Kauppi J et al.. “Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.” World journal of surgical oncology (2018). PMID: 29433514 ↗
L3RETROSPECTIVE_COHORTCited in: Chemotherapy Regimens - [41]
Rogers JE, Xiao L, Trail A et al.. “Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.” Oncology (2020). PMID: 32097933 ↗
L2NON_RANDOMIZED_TRIALCited in: Chemotherapy Regimens, Special Populations - [42]
Lee SJ, Ahn BM, Kim JG et al.. “Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.” Journal of Korean medical science (2009). PMID: 19270824 ↗
L4NON_RANDOMIZED_TRIALCited in: Chemotherapy Regimens - [43]
Guo JC, Lin CC, Huang TC et al.. “Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.” Anticancer research (2018). PMID: 29491087 ↗
L2NON_RANDOMIZED_TRIALCited in: Chemotherapy Regimens - [44]
Zhu Y, Qi X, Ni S et al.. “First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison.” Biologics : targets & therapy (2026). PMID: 41788456 ↗
L1SR_MA_RCTCited in: Targeted and Immune Therapy - [45]
Zayac A, Almhanna K. “Esophageal, gastric cancer and immunotherapy: small steps in the right direction?” Translational gastroenterology and hepatology (2020). PMID: 32190777 ↗
L2NON_RANDOMIZED_TRIALCited in: Targeted and Immune Therapy - [46]
Mendis S, Gill S. “Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.” Current oncology (Toronto, Ont.) (2020). PMID: 32368175 ↗
L5NARRATIVE_REVIEWCited in: Targeted and Immune Therapy - [47]
Xue LY, Li Y, Huang J. “[Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2023). PMID: 37078210 ↗
L5OTHERCited in: Targeted and Immune Therapy - [48]
Kojima T, Doi T. “Immunotherapy for Esophageal Squamous Cell Carcinoma.” Current oncology reports (2017). PMID: 28361224 ↗
L5NARRATIVE_REVIEWCited in: Targeted and Immune Therapy - [49]
van den Ende T, Smyth E, Hulshof MCCM et al.. “Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.” Best practice & research. Clinical gastroenterology (2018). PMID: 30551856 ↗
L5NARRATIVE_REVIEWCited in: Targeted and Immune Therapy - [50]
Kosumi K, Baba Y, Hara Y et al.. “Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors.” Annals of surgical oncology (2024). PMID: 38421531 ↗
L5OTHERCited in: Targeted and Immune Therapy - [51]
Gabiatti CTB, Martins MCL, Miyazaki DL et al.. “Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer.” Cancer medicine (2019). PMID: 31571402 ↗
L3COHORTCited in: Toxicity and Supportive Care - [52]
Lu N, Wang X, Li C et al.. “[Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2020). PMID: 32135649 ↗
L3COHORTCited in: Toxicity and Supportive Care - [53]
Papaconstantinou D, Vretakakou K, Paspala A et al.. “The impact of preoperative sarcopenia on postoperative complications following esophagectomy for esophageal neoplasia: a systematic review and meta-analysis.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2020). PMID: 32193528 ↗
L2SR_COHORTCited in: Special Populations - [54]
Goto A, Tanaka T, Shibasaki S et al.. “Circular-stapled esophagogastrostomy using the keyhole procedure after radical esophagectomy for esophageal cancer.” Esophagus : official journal of the Japan Esophageal Society (2022). PMID: 36042126 ↗
L3COHORTCited in: Special Populations - [55]
Kim HJ, Suh YG, Lee YC et al.. “Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.” Cancer research and treatment (2016). PMID: 27737537 ↗
L3COHORTCited in: Special Populations - [56]
Higgins LM, Lester-Coll NH, Ades S et al.. “'CROSS'-ing into the 'Real World': a retrospective cohort study of patients receiving trimodality and bimodality therapy for esophageal cancer.” Journal of gastrointestinal oncology (2023). PMID: 37201058 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations - [57]
Rogers JE, Xiao L, Amlashi FG et al.. “Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.” Oncology (2019). PMID: 30893708 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations - [58]
Wang Y, Lyu J, Jia H et al.. “Clinical utility of the systemic immune-inflammation index for predicting survival in esophageal squamous cell carcinoma after radical radiotherapy.” Future oncology (London, England) (2021). PMID: 34008415 ↗
L5OTHERCited in: Special Populations - [59]
Ishioka M, Yoshio T, Sasaki T et al.. “Safety and Efficacy of Self-Expandable Metallic Stent Placement Using Low Radial Force Stent for Malignant Dysphagia after Radiotherapy.” Digestion (2022). PMID: 35184058 ↗
L5OTHERCited in: Special Populations - [60]
Nam SY, Jeon SW, Lee SJ et al.. “Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients.” Gut and liver (2020). PMID: 32000467 ↗
L5OTHERCited in: Special Populations
Backlinks
- ← Esophageal Cancer Surveillance and Follow-up
- ← Esophageal Cancer Recurrent and Metastatic Disease
- ← Esophageal Cancer Recurrent and Metastatic Disease (Detailed)
- ← Esophageal Cancer Surgical Management (Detailed)
- ← Esophageal Cancer Radiation Management (Detailed)
- ← Esophageal Cancer Surgical Management
- ← Esophageal Cancer (Detailed)
- ← Esophageal Cancer Surveillance and Follow-up (Detailed)
- ← Esophageal Cancer Palliative Care (Detailed)
- ← Esophageal Cancer Palliative Care